1765P Undertreatment rates, associated factors, and survival among patients with locally advanced or metastatic urothelial cancer (la/mUC): A systematic literature review

For patients (pts) with la/mUC, systemic therapy (ST), including chemotherapy and immunotherapy, offers benefits such as improved overall survival (OS). There is no published systematic literature review (SLR) reporting on recent treatment patterns reasons for potential undertreatment in la/mUC. We aimed to comprehensively characterize rates of ST (NST) associated this population. conducted a Cochrane guideline-based SLR real-world evidence NST pts la/mUC from 2017-2022 (including study date 2015 or later). Studies English, Spanish, French, German languages any country were included. Among 2439 identified studies, total 29 reported first-line rates. Of these, 8 studies European-based, where highest UK (70%-74%), followed by Denmark (64%), the Netherlands (48%-53%), Spain (40%). Twelve US-based 14%-60%; 9 rest world, Japan, Canada, Russia, 9-63%. percentage NST, 6 clinical characteristics untreated compared those treated pts. describing statistical analyses performed only 2, that older age poor performance status significantly NST. survival, median OS was 2.0-6.9 months 9.2-34.5 receiving ST. Our analysis relevant showed there significant heterogeneity populations studied across settings, geographies. Notwithstanding, substantial proportion are undertreated evidenced large variability reported. Future research needed fully elucidate undertreatment, given availability effective treatments